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Abstract
This paper provides an overview of the regulation of quality assurance for genetic testing in
Australia and New Zealand and outlines the steps currently being taken to critically appraise and
improve the regulatory framework in each country. It aims to contextualize this framework within
the broader context of quality and patient safety concerns; and to draw together the concerns and
recommendations of the various organizations that have been working to improve quality
assurance in this area.
Background
Genetic tests have the capacity to generate information
that may have a profound effect on the tested individual.
Test results may affect the individual's treatment deci-
sions, and choices about reproduction, as well as having
potential implications for his or her family members.
Given this, it is vital that genetic testing occur within a
framework that promotes and protects patient safety and
well being. One aspect of this framework is quality assur-
ance, which refers to measures to ensure the quality and
consistency of genetic testing.
The purpose of this paper is to provide an accurate, up to
date picture of the current state of the regulatory frame-
work governing quality and safety of genetic testing in
Australia and New Zealand. We hope that, given the ongo-
ing reviews of and changes to this regulatory framework,
this summary will provide a useful snapshot of the current
regulatory environment for those working with or inter-
ested in genetic testing and patient safety.
Genetic testing in Australia and New Zealand
Genetic tests are preformed by a range of private and pub-
lic organisations in Australia and New Zealand. As of
2005, over 220 genetic tests were available in Australia
and 45 laboratories were providing genetic testing services
[3]. These laboratories are generally attached to or affili-
ated with a public hospital or university. Tests are also
provided by private genetic testing or pathology laborato-
ries. In addition, some government departments have lab-
oratories that conduct genetic testing, for example
forensic laboratories. Some tests are also carried out in
research laboratories, particularly tests that are still in the
research phase or for which there is little demand.
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Seven laboratories in New Zealand offer diagnostic testing
for approximately 75 genetic disorders [3]. The two main
laboratories are the Diagnostic Genetics Department at
Auckland City Hospital, and Canterbury Health Laborato-
ries, Christchurch. Outside major city centres, testing serv-
ices are provided through outreach clinics. The current
range of genetic tests available in New Zealand depends
on clinical demand, the focus of individual laboratories
and the available funds from each District Health Board
(DHB).
What is quality assurance in genetic testing?
Quality assurance in genetic testing refers to measures to
ensure that laboratories adhere to high standards of care
and undertake testing that is justified and accurate. Qual-
ity assurance in genetic testing fits within the broader of
concept of patient safety and wellbeing, as it is one ele-
ment of a range of strategies used within the healthcare
system to ensure that patients receive appropriate, effec-
tive treatment on a voluntary and informed basis. These
strategies include pre-and post-test measures, such as
effective identification of individuals at increased risk of a
genetic disorder, genetic counselling, appropriate privacy
and confidentiality regulation and/or legislation. Genetic
tests can reveal highly personal information about an
individual and in many cases other family members,
hence appropriate measures should be in place to protect
the privacy and confidentiality of the results, to prevent
unauthorised access and possible misuse of this sensitive
information. This paper focuses on the regulation of qual-
ity assurance of genetic testing, so only the test stage of the
testing process is examined in detail.
At the test stage, measures to ensure quality assurance fall
into two categories – (1) the safety, accuracy and utility of
a test; and (2) the competency of the laboratory and its
staff in performing that test. The safety, accuracy and util-
ity of a test are important issues in patient safety because
a lack of any one of these characteristics may lead to the
patient receiving misleading or unhelpful information.
For example, there is debate about whether genetic tests
should be preformed if there is not available treatment for
the condition. The genetic condition of Huntington's dis-
ease provides a relevant example. Although there is cur-
rently no cure for Huntington's disease, some at risk
people choose to have the genetic test and use the infor-
mation to inform his or her reproductive decisions. Tests
are judged in relation to analytical validity, clinical valid-
ity, and clinical utility to ensure they are safe and accurate.
Analytic validity is the ability of a test to detect the trait it
seeks to measure. Clinical validity is the capacity of the
test to predict a specific clinical outcome. Clinical utility
refers to the actual usefulness of the test in improving
health and well-being of the persons tested and largely
rests on whether the information provided by the test can
be followed by effective and safe preventive or therapeutic
interventions.
The second aspect of quality assurance at the test stage is
laboratory competency. If tests are not performed cor-
rectly, using the right equipment, or the laboratory staff
lack the skills to perform the tests, then the results may be
inaccurate. Further, the laboratory should be competent
in managing samples and results, maintaining confidenti-
ality and privacy, and in delivering results appropriately.
Administrative failures may lead to the loss of results, mix
ups or breaches of privacy and confidentiality, harmful to
the patient's interests. It is therefore important to ensure
that laboratories are competent to undertake and manage
the tests they offer.
Quality assurance regulation general framework
Genetic testing in Australia and New Zealand is subject to
the more general scheme of laboratory and test accredita-
tion, although some specific regulations and guidelines
do apply. This reliance on a generic regulatory framework
is largely due to the fact that the aspects of genetic testing
and genetic information that differ from general testing
and medical information are most relevant at the pre- and
post-test stage. For example, genetic counselling is neces-
sary prior to, and following, some genetic tests due to the
particular ramifications of the results, but this is regulated
largely through guidelines for professionals working in
genetics, rather than at the test stage [see, eg, [4]].
This general quality assurance scheme is comprised of leg-
islative requirements, accreditation standards, and guide-
lines developed and administered by a number of
organizations. In both Australia and New Zealand, the
national government acts as the primary regulatory body
for healthcare services through a national health depart-
ment in collaboration with a number of government advi-
sory bodies. Regulatory bodies also include laboratory
and professional accreditation bodies, and consumer pro-
tection agencies. In addition, professional organizations
act as advisory bodies, offering independent guidelines
and standards of practice. There is some overlap between
the Australian and New Zealand schemes.
General healthcare framework for Australia
The regulatory framework governing the provision of
genetic tests sits within the broader healthcare system and
so it is important to have a sense of the way health services
are provided and funded in Australia and New Zealand.
The Australian health care system is largely regulated (and
partially funded) at the State and Territory level; however
the Federal Government also provides funding and has a
regulatory role. Medical services are provided through
both the public and private sectors, and public subsidies
(Medicare benefits) are available for many services.Australia and New Zealand Health Policy 2006, 3:13 http://www.anzhealthpolicy.com/content/3/1/13
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The Federal government regulates the provision of pathol-
ogy services only indirectly through the administration of
the Medical Benefits Schedule (MBS) by withholding sub-
sidies for pathology services from laboratories that are not
appropriately accredited [[5], p4]. It also regulates specific
tests, whereby only accredited tests are subsidised. The
States and Territories do have the power to regulate
pathology services, however only Victoria has enacted spe-
cific legislation in this area [6]. The test and laboratory
accreditation schemes are outlined below; however Figure
1: Regulation and accreditation pathways for genetic test-
ing in Australia provides a summary of these schemes and
their interaction.
General healthcare framework for New Zealand
The Ministry of Health Manatû Hauora (MOH) is the New
Zealand governmental agency that issues guidelines and
policy for medical services throughout New Zealand [7].
The MOH distributes funding to District Health Boards
[8] which are in turn responsible for funding and deliver-
ing health and disability services in their district. DHB lab-
oratories perform the majority of genetic tests, and are
usually based in public hospitals.
Testing services and laboratories are regulated to some
degree by the MOH as part of its responsibility for main-
taining the National Health Service. The MOH regulates
some requirements for laboratory quality and auditing, as
well as defining the mechanisms through which laborato-
ries are funded [[9], p9]. Laboratory accreditation in New
Zealand is administered by an agency called International
Accreditation New Zealand (IANZ). The New Zealand
schemes for introducing new tests and ensuring labora-
tory quality standards are discussed below, however the
regulation and accreditation pathways are also summa-
rised in Figure 2: Regulation and accreditation pathways
for genetic testing in New Zealand.
Test accreditation
Australia
In Australia, the use of tests is regulated partially through
funding incentives provided by the Federal Government.
For tests to attract a government subsidy, an application
must be made to the Medical Services Advisory Commit-
tee (MSAC) [10], which advises the Federal Government
on new medical technologies and procedures. MSAC
bases its assessment on the safety, effectiveness (including
validity and utility), and cost-effectiveness of the test in
accordance with the MSAC guidelines [11]. MSAC makes
recommendations to the Federal Minister for Health and
Ageing, who then decides whether the test should receive
public funding. If successful, the test will be listed on the
MBS and Medicare benefits will be available.
This system creates an incentive for laboratories to pro-
vide only tests that have been accredited, as otherwise
patients will be unable to apply for Medicare benefits to
offset the cost of the test. It does not, however, prevent
unaccredited tests from being offered and therefore does
not wholly protect patient safety.
Further, the MSAC submission process can be both time-
consuming and expensive, which may discourage the sub-
mission of some tests where the process may not be cost-
effective. Completing the MSAC application process can
be labour intensive and time consuming as applicants
must attend a pre-lodgement meeting and then complete
a forty-three page application form. In completing the
application, the applicant should make reference to the
2005 guidelines which are 100 pages long. This may dis-
courage manufacturers of diagnostic tests for rare genetic
conditions and a small potential market from applying to
MSAC for Federal funding [40].
New Zealand
Unlike Australia, New Zealand has not introduced a for-
mal system for validating new genetic tests and the MOH
has no formal role in assessing new tests. Rather, new tests
are introduced in response to clinical demand, or as a
result of the individual interests of each laboratory [[9],
p8]. Each DHB is responsible for funding genetic tests,
and are therefore responsible for the quality of testing in
their regions. Genetic tests are also not listed on the Labo-
ratory Services Schedule, which lists tests available for
public funding in New Zealand, as determined by the Lab-
oratory Services Advisory Group. There is also no advisory
body in New Zealand responsible for determining
whether a genetic test should be publicly funded [[38],
p13].
Despite this lack of formal assessment of new tests, those
that are offered in New Zealand tend to be for common
genetic conditions and are usually well validated. Where a
patient requires a test for a less common condition, the
sample will often be sent to a laboratory outside New Zea-
land [[9], p9]. Further quality assurance is provided
through the laboratory accreditation scheme, as a labora-
tory cannot receive healthcare subsidies for any test unless
it has received IANZ accreditation to perform that test [[9],
p13].
In vitro diagnostic devices
It should be briefly noted that a new scheme for regulating
in vitro diagnostic devices (IVDDs), which will cover
some genetic tests, is being developed by the Australian
Therapeutic Goods Administration (TGA). Development
of the scheme was initiated in January 2002 by the TGA,
and an agreement in principle to the proposed regulatory
framework for IVDDs was made by Australian HealthAustralia and New Zealand Health Policy 2006, 3:13 http://www.anzhealthpolicy.com/content/3/1/13
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Ministers' Advisory Council (AHMAC) members on 23
October 2003. An outline of the framework can be found
at the TGA website [47].
The TGA is currently developing risk-based classifications
for IVDDs, and this scheme will include genetic tests. An
IVDD will be placed in one of four risk classes:
Regulation and accreditation pathways for genetic testing in Australia Figure 1
Regulation and accreditation pathways for genetic testing in Australia.Australia and New Zealand Health Policy 2006, 3:13 http://www.anzhealthpolicy.com/content/3/1/13
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￿ Class I: no public health risk/low personal risk;
￿ Class II: low public health risk/moderate personal risk;
￿ Class III: high personal risk/moderate public health risk;
￿ Class IV: high public health risk.
The TGA has given examples of genetic tests that will fall
into some of these classes. Class II IVDDs are tests "that
detect the presence or exposure to infectious agents that
are not easily propagated in the Australian population or
that cause self-limiting diseases" and present a moderate
individual risk, where the test is not intended to be the
sole diagnostic method or "where an erroneous result
rarely puts the individual in immediate danger". This will
include some genetic tests such as thrombophilia muta-
tion screening tests.
Class III IVDDs are tests that provide the "critical, or sole,
determinant for the correct diagnosis", where "an errone-
ous result would put the patient in an imminent life-
threatening situation, or would have a major negative
impact on outcome". The TGA also states that these are
tests that "may also present a high individual risk because
of the stress and anxiety resulting from the information
and the nature of the possible follow-up measures". This
class of IVDDs will include predictive genetic screening
tests for conditions that will usually have "a substantial
impact on the life of the individual", such as tests for phe-
nylketonuria (Guthrie test), Huntington's Disease, Cystic
Fibrosis [47].
Some comparisons
The major difference between the Australian and New
Zealand systems is that Australia has developed a central-
ised process for assessing new genetic tests before they can
be offered to patients. Such a system is useful, as it ensures
that all tests are consistently evaluated for analytical and
clinical validity as well as clinical utility before they are
provided to the public. However, it appears that in New
Zealand, for the most part, only tests that have been well
validated either within the country or elsewhere are
offered, and at present there is no evidence that this lack
of formal regulation is highly problematic. This may be
Regulation and accreditation pathways for genetic testing in New Zealand Figure 2
Regulation and accreditation pathways for genetic testing in New Zealand.Australia and New Zealand Health Policy 2006, 3:13 http://www.anzhealthpolicy.com/content/3/1/13
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because health services in New Zealand are more locally
integrated than their Australian equivalents.
Laboratory accreditation
Australia
The Federal Government uses funding incentives to
encourage laboratories to become accredited (and hence
maintain adequate laboratory standards). To receive
Medicare payments for medical services, a laboratory
must be accredited in the relevant testing services, comply
with the NPAAC guidelines and be designated an Accred-
ited Pathology Laboratory.
Accreditation of testing services is administered by the
National Association of Testing Authorities, Australia
(NATA). NATA is an independent, private, not-for-profit
company operating as an association. It is owned and gov-
erned by its members (registered laboratories) and repre-
sentatives from industry, government and professional
bodies (such as the Royal College of Pathologists). NATA,
as a member of the Asia-Pacific Laboratory Accreditation
Cooperation (APLAC), regularly participates in audits by,
and of, its mutual recognition partners in Europe, North
America and the Asia-Pacific region. NATA operates an
accreditation scheme for laboratories and is the Federal
Government-endorsed accreditation body for establishing
competent laboratory practice. This was outlined in the
Memorandum of Understanding between NATA and the
Commonwealth government [13].
Laboratories apply directly to NATA for accreditation in
types of medical testing. NATA's medical testing accredita-
tion scheme is based on the relevant guidelines issued by
the National Pathology Accreditation Advisory Council
(NPAAC). NPAAC consists of representatives from the
DHA, the State and Territory departments of health, and
from peak professional organizations including the Royal
College of Pathologists of Australasia (RCPA) and the
Human Genetics Society of Australasia (HGSA), among
others. NPAAC advises the Commonwealth, State and
Territory Health Ministers on matters relating to the
accreditation of pathology laboratories.
NATA accreditation standards are developed with refer-
ence to international standards (such as ISO) for labora-
tory competency in consultation with the RCPA. Such
international standards are incorporated by a requirement
that NPAAC guidelines be read "with" the standards, such
as the Laboratory Accreditation Standards and Guidelines for
Nucleic Acid Detection Techniques which are to be read with
AS ISO/IEC 17025:1999, General requirements for the com-
petence of testing and calibration laboratories. This adds an
extra layer of quality assurance to the requirements put in
place by NATA and NPAAC.
Once laboratories apply for accreditation, NATA conducts
an inspection to determine whether they satisfy NPAAC
requirements and, if successful, they then become mem-
bers of NATA. They must undergo periodic future inspec-
tions to maintain accreditation [[5], p2]. In accrediting a
laboratory, NATA endorses its competency to undertake
testing, which can include genetic testing. Professionals
from the pathology industry volunteer to act as peer
reviewers for NATA accreditation assessments. Peer
reviewers undergo accreditation assessment training and
work with a NATA staff officer to ensure objectivity and
consistency [[5], p11].
To obtain NATA accreditation and receive Medicare bene-
fits laboratories must comply with the standards and
guidelines released by NPAAC [14]. NPAAC standards
and guidelines cover many aspects of laboratory practice
including: laboratory ethics; quality systems; staffing,
supervision and consultation; facilities; test ordering,
analysis, and follow-up; occupational health and safety;
and internal and external auditing for quality assurance
[15]. In particular, NPAAC's Standards for Pathology Labo-
ratories requires that patient wellbeing and confidentiality
be the primary considerations of the laboratory when per-
forming tests [[15], Standard 1]. This means that no per-
son should disclose patient or test information to anyone
other than the requesting medical practitioner, or other
medical practitioner currently treating the patient, except
in some defined circumstances outlined by state and fed-
eral privacy legislation. NPAAC requires that human sam-
ples, tissues and remains be treated with due respect.
Finally, it is the responsibility of the laboratory to ensure
that the quality of their work is not affected by any
improper pressure, be it financial, commercial, or other-
wise.
NPAAC standards require laboratories to undergo exter-
nal quality assurance testing programs, such as those pro-
vided by the RCPA, and to perform to an acceptable
standard [[15], Standard 9]. Data from these external pro-
grams are made available to NATA during assessment [[5],
p14]. Where there is no external proficiency program
available, laboratories are required to undergo inter-labo-
ratory comparisons and/or analysis of reference and con-
trol materials [[15], Standard 9].
Once accredited, to receive Medicare benefits for tests, a
laboratory then must apply to the Minister for Health and
Ageing (the Minister) via Medicare Australia for approval
to become an Accredited Pathology Laboratory (APL), as
only APLs may obtain Medicare benefits for pathology
services provided [[12], s 16A(2)(b)]. The approval proc-
ess and requirements are is provided by the Health Insur-
ance Act 1973 (Cth) (HI Act) [[12], s 23DN(1), (2)].
Accreditation decisions must be made in accordance withAustralia and New Zealand Health Policy 2006, 3:13 http://www.anzhealthpolicy.com/content/3/1/13
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the HI Act and the Health Insurance (Accredited Pathology
Laboratories-Approval) Principles 1999 (Cth). Laboratories
applying for accreditation must have undergone a NATA
inspection prior to application and include the NATA
inspection report with their application. Only those
pathology services approved by NATA will be eligible for
Medicare benefits if accreditation is obtained.
Without NATA accreditation, and subsequent approval of
the laboratory and personnel by Medicare Australia, labo-
ratories are unable to access the benefits of Medicare pay-
ments for their services. In the case of a breach of the
principles outlined by NPAAC, NATA, and Medicare Aus-
tralia, Medicare benefits and accreditation may be
removed. Inability to provide tests at subsidised rates may
adversely affect a laboratory's capacity to provide compet-
itively-priced tests, and hence the revocation of Medicare
benefits is a strong incentive for laboratories to achieve
accreditation.
Until recently, Victoria had an independent structure for
accreditation of all pathology laboratories in the state,
regardless of whether they seek Medicare payments [16].
The Pathology Services Accreditation Board, on behalf of
the State Minister for Health, governed accreditation pro-
cedures and legislation as defined by the Pathology Services
Accreditation Act 1984 (Cth) in accordance with NPAAC
standards and the NATA/RCPA scheme [[17], s9]. How-
ever, this act was repealed in 2003 by section 14(1) of the
Health Legislation Amendment Act 2003 (Vic), and the
Board consequently dissolved in January 2004 [43].
Genetics-specific regulation and accreditation
NPAAC standards do make some specific provisions for
the unique challenges raised by genetic testing. Previ-
ously, under the Laboratory Accreditation Standards and
Guidelines for Nucleic Acid Detection Techniques 2000 ver-
sion, NPAAC recognised that "the implications of labora-
tory diagnosis of genetic disease are different from those
of many other areas of laboratory testing" and as a result
draws a distinction between two types of testing – diag-
nostic genetic tests (Class A) and predictive, carrier and
prenatal genetic tests (Class B). For Class A tests, only ver-
bal consent is required and there is no requirement for
pre-test counselling. By contrast, Class B tests are carried
out on non-symptomatic patients who must receive pre-
and post-test counselling and must provide formal, writ-
ten consent.
In addition, laboratories were required to take responsi-
bility for ensuring the formal consent has been obtained
and counselling provided. For Class B tests, where the lab-
oratory suspects that proper consent has not been
obtained, it is required to contact the referring practitioner
to ensure informed consent has been obtained before it
may undertake testing [[20], para 1.2]. Under the same
standard, laboratories are prohibited from providing
patient-initiated tests, such as mail-order testing.
This description of DNA testing for inherited genetic dis-
orders – divided into Class A and Class B – has been
revised in version 6.1 of the NPAAC standards and guide-
lines implemented in August 2006 [1,42]. This change
was deemed necessary because, a particular test could
move between Class A and Class B on a case by case basis,
depending on its use and circumstances, which has caused
confusion. The latest draft of the NPAAC guidelines for
Nucleic Acid Detection (set to be approved in 2006) has
attempted to dispel this confusion by changing the classi-
fication system. The Level 1 (standard DNA test) and Level
2 DNA test (complex issues) categorisation allows classifi-
cation to vary regardless of the test based on the implica-
tions of the testing situation.
Level 1 DNA tests (standard) include a) DNA testing for
confirmation of diagnosis where the patient has a clinical
diagnosis, symptoms, or a family history of an established
inherited disorder or any other DNA test that doesn't fall
into level 2; b) Neonatal screening programs.
Level 2 DNA tests are considered those tests which could
potentially to lead to complex clinical issues. Level 2 tests
would include predictive or presymptomatic DNA testing,
and tests for conditions for which there is no simple treat-
ment. In these cases, specialised knowledge is often neces-
sary to determine the need for testing (i.e. the test should
be requested by a specialist rather than any physician).
Level 2 tests should be accompanied by both pre- and
post-test professional genetic counselling and may also
require specific written consent [[42], Table 1.1].
Version 6.1 of the NPAAC document will require labora-
tories to review the categorisation of DNA tests for human
inherited disorders with the guidance of representative
professional bodies. Classification of a test as Level 1 or
Level 2 will take into consideration "resources, current
knowledge, circumstances, the type of condition being
tested for, and the implications of the DNA test result for
the patient and family".
Laboratories providing genetic testing in Australia are also
covered by the influential, if not binding, information
papers, guidelines and principles released by the National
Health and Medical Research Council which outline some
of the ethical aspects of genetic testing [see, eg, [21]], and
policies released by the HGSA [22].
New Zealand
International Accreditation New Zealand (IANZ) is the
Crown-owned, user-funded authority providing accredi-Australia and New Zealand Health Policy 2006, 3:13 http://www.anzhealthpolicy.com/content/3/1/13
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tation for a range of laboratories and related technical
services in New Zealand, including pathology laboratories
[9]. IANZ Laboratory Accreditation for Medical Testing
complies with NZS/ISO 15189:2003 Medical Laboratories –
Particular Requirements for Quality and Competence [23].
This standard replaced the New Zealand Code of Labora-
tory Management Practice for all IANZ accreditation as of
1 January 2004 [24]. The IANZ accreditation system and
the specialist technical peer-review process include the
assessment of laboratory staff. IANZ further requires that
laboratories offering genetic testing comply with the Aus-
tralasian NPAAC guidelines [see list of applicable guide-
lines at [25]].
In addition, both the HGSA and the RCPA offer quality
assurance assessment for genetic tests by carrying out pro-
ficiency testing for some common tests [[9], p13]. Many
laboratories also participate in College of American
Pathologists (CAP), and/or European Molecular Quality
Network (EMQN) programs [Personal communication
(March 14, 2005) Dr. Karen Snow Bailey, Director of
Diagnostic Genetics, LabPlus, Auckland District Health
Board, New Zealand]. IANZ has entered into a mutual rec-
ognition arrangement with NATA (the Australian accredi-
tation body) recognizing equivalency of their standards of
accreditation [26]. New Zealand laboratories are therefore
also subject to NPAAC guidelines, as compliance with
these is a prerequisite of NATA accreditation.
The IANZ reports annually to the MOH. If the ministry is
informed of a breach of the IANZ guidelines, action is
taken through the funding agreements with the DHBs,
rather than by taking action against the individual labora-
tory. The DHB is responsible for ensuring the quality of
the laboratories to which it provides funding [9].
Genetics-specific regulation and accreditation
As IANZ uses NPAAC standards, New Zealand laborato-
ries are subject to the same standards in relation to genetic
testing as described below. New Zealand laboratories are
also subject to HGSA policies, but not to NHMRC guide-
lines.
Australia and New Zealand overlap and the joint Trans 
Tasman scheme
From the preceding discussion, it becomes clear that Aus-
tralia and New Zealand have integrated their two quality
assurance systems to some degree. This integration is sum-
marised in Figure 3: Integration of regulation and accred-
itation pathways for genetic testing in Australia and New
Zealand.
Recently, the two countries took steps towards further
integration of their schemes in December 2003 by accept-
ing a joint proposal for a Trans-Tasman agency for the reg-
ulation of therapeutic products [[27]; 28]. The proposed
agency will replace Australia's TGA and New Zealand's
Medsafe, and will include regulation of materials for
genetic testing and IVDDs. At the time of writing (August
2006), considerable progress towards establishing the
agency, to be known as the Australia and New Zealand
Therapeutic Products Agency, had been made. The first
round of public consultations were held in June 2006 in
Australia and New Zealand and the second round is pro-
posed for September 2006 and a third and final round for
March 2007 [46]. According to the Therapeutic Products
Interim Ministerial Council, the scheme is expected to
commence in the second half of 2007 [49].
Establishing the Trans-Tasman agency is an encouraging
step. It will improve consistency in practices and stream-
line quality assurance procedures, which will be particu-
larly important in this region. Samples are often sent
between Australia and New Zealand for testing, for exam-
ple in cases where one country lacks capacity in a particu-
lar test, and improved consistency and integration can
only further develop quality assurance mechanisms by
removing gaps in regulatory coverage. Further, this joint
approach will better equip each country to address regula-
tory issues raised by new, innovative technologies as they
emerge [45].
Reviews of regulatory and accreditation systems
Australia and New Zealand have been pro-active in their
attempts to identify and address the problems in their sys-
tems of quality assurance with respect to genetic tests.
Genetic testing is an area of medical technology that con-
tinues to develop rapidly. For this reason, the Australian
and New Zealand accreditation schemes are subject to reg-
ular reviews to assess whether they effectively ensure
appropriate quality standards in genetic testing. These
reviews have highlighted a number of areas for improve-
ment. We now describe the findings of recent reviews and
present a summary of the common themes of these eval-
uations.
Note that some of these reviews referred to the Health
Insurance Commission (HIC), which from October 2005
has been known as Medicare Australia. These references
have been left as they were in the original reviews, how-
ever all references to the HIC in this section should be
taken as now referring to Medicare Australia. The HIC
Annual Report 04–05 provides information on the changes
to the Commission and the relevant legislative amend-
ments [[44], Ch 2.2].
Australian reviews
Australian Law Reform Commission inquiry
In 2001, the Australian Law Reform Commission (ALRC),
a permanent, independent federal statutory corporationAustralia and New Zealand Health Policy 2006, 3:13 http://www.anzhealthpolicy.com/content/3/1/13
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providing advice to the Australian Federal Government on
areas of law reform, began a comprehensive two-year
inquiry into the protection of genetic information in Aus-
tralia (ALRC Inquiry) [30].
The ALRC Inquiry included a review of some aspects of
pathology service provision, and identified a number of
concerns in relation to quality assurance and genetic test-
ing, including:
￿ the lack of independent assessment of non-accredited
laboratories;
￿ failure of current accreditation standards to address
issues such as informed consent, privacy, and chain of cus-
tody of samples;
￿ the possible provision of genetic tests direct to the pub-
lic, without proper consent or counselling [[30], Ch 11].
The ALRC made a range of recommendations directed at
addressing these concerns. It recommended that:
￿ An oversight body for issues around genetic testing and
genetic information, known as the Human Genetics Com-
mission of Australia (HGCA) be established [[30], Recs 5–
1 to 5–9];
￿ The HGCA should develop codes of practice and advice
relating to the provision of technical and ethical standards
for genetic testing services provided direct to the public
[[30], Recs 11–2 to 11–7];
￿ The HGCA should develop genetic testing and counsel-
ling practice guidelines, in consultation with HGSA, state
genetic services, and other interested parties [[30], Rec 23–
2];
Combined regulation and accreditation pathways for genetic testing in Australia and New Zealand Figure 3
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￿ NPAAC should further develop ethical standards for
medical genetic testing, in consultation with the NHMRC
and the proposed HGCA;
￿ NPAAC should examine how to assess compliance with
accreditation standards in relation to consent, counselling
and other ethical considerations; and NATA should
develop training programs to equip its officers and peer
assessors to verify compliance [[30], Recs 11–2 to 11–4];
￿ The Commonwealth Government should amend the
Therapeutic Goods Act 1989 (Cth) to better regulate genetic
tests provided directly to the public [[30], Recs 11–2 to
11–5].
To date, only some of the ALRC's recommendations have
been implemented. However, one notable success is the
Federal Government's commitment in the 2005 Federal
Budget to provide $7.6 million over four years to establish
an independent expert advisory body on human genetics.
The new body, named the Human Genetics Advisory
Committee, is now a central committee of the NHMRC
[31]. This body satisfies the inquiry's core recommenda-
tion for the establishment of the HGCA, and is a signifi-
cant step towards more effective regulation of genetic
testing, including quality assurance. More information
about the functions and membership of the committee
can be found on the NHMRC website [52]. The Federal
Government is currently preparing a response in relation
to the remaining recommendations in the ALRC Inquiry
report [31].
Department of Health and Ageing reviews
Also in 2001, the Federal Department of Health and Age-
ing (DHA) commissioned a major independent review of
the Australian pathology laboratory accreditation arrange-
ments (Pathology Accreditation Review). This review was
the first comprehensive evaluation of the arrangements
since their introduction [[5], p1]. The review found that
"the current Australian pathology accreditation arrange-
ments are fundamentally sound and should be main-
tained" [[5], Rec 2.1]. However, the review also identified
a number of areas in which accreditation could be
improved. These included:
￿ Lack of Federal power to directly regulate pathology
services [[5], p4].
￿ Delays in current management of non-compliance in a
small number of laboratories, which have resulted from
delays in arranging or conducting NATA/RCPA assess-
ments; delays in referral of non-compliant laboratories to
the HIC; due to NATA's internal appeal process; or due to
administrative appeal procedures [[5], ppi, 4].
￿ As most laboratories are regulated through administra-
tion of the MBS, the small number of laboratories that do
not seek Medicare benefits are unregulated [[5], pi]. As a
result, it is difficult for the HIC to enforce compliance
with NPAAC standards within these laboratories [[5], p4].
The Pathology Accreditation Review resulted in 37 recom-
mendations, the great majority of which were accepted by
the DHA in its response [32]. Many of these recommenda-
tions were detailed and focused on very specific aspects of
the accreditation process, therefore only a few more gen-
eral, overarching recommendations are outlined here. In
particular, the Pathology Accreditation Review recom-
mended that an evaluation be made of the costs and ben-
efits of enacting State and Territory legislation to
complement the national regulatory system. As the States
and Territories have the power to directly regulate pathol-
ogy services, such legislation could address the lack of reg-
ulation of laboratories that fall outside the current
accreditation system because they do not access MBS sub-
sidies [[5], Rec 2.2]. The ALRC Inquiry made a similar rec-
ommendation [[30], Rec 11–1].
Finally, the Pathology Accreditation Review recom-
mended increasing the sanctions open to the HIC to deal
with non-compliant laboratories. The HIC should be able
to:
￿ require that laboratories participate in re-inspection;
￿ to notify the public of laboratories rated 'Non-Compli-
ant with Moderate or Serious Risk';
￿ to require laboratories to notify referring medical practi-
tioners and/or consumers of their non-compliant status;
and
￿ to revoke Medicare benefits [[5], Rec. 6.1].
In relation to the need to identify an organisation or indi-
vidual with clear responsibility for the oversight of the
pathology quality assurance system, the Australian Coun-
cil for Safety and Quality in Health Care (ACSQHC) has
undertaken preliminary work to consider structures that
could oversee standard setting and quality monitoring in
this area. Therefore, the Pathology Accreditation Review
recommended that the DHA allocate responsibility for the
oversight of pathology quality assurance systems to a
DHA senior officer until the ACSQHC takes further action
[[5], Rec. 6.5].
As a result of this review, the Commonwealth Govern-
ment has announced moves to improve the standards of
pathology laboratory testing and to identify laboratories
that do not meet required standards [33]. The DHA con-Australia and New Zealand Health Policy 2006, 3:13 http://www.anzhealthpolicy.com/content/3/1/13
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firmed in 2003 that the Australian Health Ministers' Advi-
sory Council Group on Human Gene Patents and Genetic
Testing was considering the establishment and implemen-
tation of an improved quality assurance and accreditation
scheme [[30], p339].
The DHA has instigated two other reviews of the regula-
tion of pathology services. One, the Review of the Common-
wealth Legislation for Pathology Arrangements under
Medicare, was completed in 2002 (DHA Review) [34]; the
other, the Review of enforcement and offence provisions of the
Health Insurance Act 1973 as they relate to the provision of
pathology services under Medicare (Enforcement Provisions
Review) was completed in August 2005 [35]. These
reviews examined in detail some aspects of the regulatory
framework for pathology services, including enforcement
and offence provisions, compliance arrangements, fund-
ing and accreditation.
The DHA Review noted two main challenges relevant to
quality assurance in genetic testing, to which the Federal
Government has responded positively. First, the govern-
ment is taking steps review the current qualification
requirements and the approval process for Approved
Pathology Practitioners to ensure, among other things,
regular checks on staff competency (in line with Recom-
mendation 11) [[34], Rec. 11] [36].
Second, the new Pathology Laboratory Principles that
came into effect on 1 January 2003 act on part of Recom-
mendation 13 to:
￿ strengthen links between the NATA accreditation proc-
ess and approval as an APL;
￿ strengthen the HIC's powers in relation to laboratories
operating below standard; and
￿ develop links between participation in a quality assur-
ance program and notification of the results [[34], Rec. 13,
36].
The DHA Review also considered there was a need for
greater enforcement provisions, recommending the estab-
lishment of new offences, strengthening of the Medicare
Participation Review Committee and "introducing a sys-
tem of direct administrative action" by HIC [[34], Rec.
14].
In August 2005, Phillip Fox Lawyers released the govern-
ment commissioned Enforcement Provisions Review
report [50]. This Review was commissioned by the DHA
in response to recommendations 14 and 15 of the previ-
ous DHA Review. The Enforcement Provisions Review
makes a series of recommendations aimed at clarifying
and strengthening the provisions of the Health Insurance
Act 1973 (Cth) (HI Act). While there is not space here to
summarise the wide range of issues addressed in the
report, its primary recommendations focus on making it
clearer that certain relationships between pathology pro-
viders and requesting practitioners are prohibited, and
ensuring that appropriate enforcement action is available
where breaches occur. In particular, the Review clarifies
that provision of, or demand for, financial or other incen-
tives for referral for pathology services breaches the letter
and spirit of the HI Act, particularly s129AA and s129AAA
(p2 Section 1.11). To give one example, the Review rec-
ommends that a Medicare benefit be reinstated to cover
the costs incurred by general practitioners in collection of
samples for pathology testing (particularly in rural and
remote areas) (Recommendation 33), which would pre-
vent the provision of incentives by the pathology provider
in the form of disposables for sample collection.
In May 2006, the government accepted the bulk of Phillip
Fox's recommendations and has and agreed to act on
these as swiftly as possible to expedite clarification and
strengthening of the enforcement and offence provisions,
and simplification of the sanctions process [51]. This will
include the recommended amendments to the HI Act, and
additions to and consolidation of s129AA and s129AAA
(which will likely involve the repeal and replacement of
the provisions, rather than amendment). In some cases
the government agreed to take action supporting the
intent of the recommendation, rather than the specifics
proposed by the review. These included Recommendation
2, that the HI Act be amended to enable the HIC to
address "serious and imminent risk to public health" by
suspending an APL approval without a hearing to the
APA. The government agreed, in conjunction with Medi-
care, to explore options and determine minimum require-
ments for this action to be taken [51].
National Public Health Partnership report
Until July 2006, the National Public Health Partnership
(NPHP) was a sub-committee of the Australian Health
Ministers' Advisory Council (AHMAC), established under
a Memorandum of Agreement between the Federal, State
and Territory governments in 2003 [37,53]. During its
operation, the NPHP compiled An Overview of Public
Health Surveillance of Genetic Disorders and Mapping of Cur-
rent Genetic Screening Services in Australia, released in Octo-
ber 2002, to summarize the current organization and
availability of genetic services, and the legislation in place
to regulate these services (NPHP Overview).
The report identified a number of issues, and recom-
mended that a national approach be taken to deal with
them. The issues it identified that relate to quality assur-
ance in genetic testing were that:Australia and New Zealand Health Policy 2006, 3:13 http://www.anzhealthpolicy.com/content/3/1/13
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￿ Existing legislation used to regulate genetic testing is not
always specific to genetics. Some states rely on general fed-
eral regulations that may be used to cover genetic testing.
￿ Although there is widespread voluntary compliance
with NPAAC, HGSA, and NATA guidelines, there are no
direct measures to combat non-compliance.
￿ The division of healthcare funding between the Federal
Government and State and Territory governments raises
issues about ensuring equitable access to tests.
New Zealand reviews
Two major reviews of genetic testing practices have been
undertaken in New Zealand in the past three years. The
first, a report by Dr Diana Sarfati for the National Health
Committee (NHC) [9] released in 2002 (Sarfati Report),
provides an overview of genetic testing in New Zealand in
relation to international standards of best practice. The
report did not focus on identifying areas for improvement
nor did it make any recommendations, but did note a
number of areas of concern, such as:
￿ The lack of formal quality control programmes to ensure
standards of quality for genetic testing in some laborato-
ries.
￿ The capacity of current accreditation mechanisms to
detect poor laboratory practice.
￿ The exclusion of research laboratories providing clinical
testing from IANZ accreditation requirements, as they
may lack quality assurance processes.
￿ IANZ's lack of power to enforce compliance. For exam-
ple, there is no requirement for it to contact the MOH
when it suspects that a laboratory is not meeting its stand-
ards Even when the MOH is informed, its only means of
pressing for compliance is funding agreements with
DHBs, which are responsible for quality of testing services
[9,13,14].
The report also noted that the NHC was working on a
framework for assessing new technologies, including
genetic tests, that would, among other things, examine
their safety and effectiveness [[9], p9].
In 2003, the National Advisory Committee on Health and
Disability of New Zealand issued a report for the NHC,
Molecular Genetic Testing in New Zealand (NHC Report)
[38]. This document built on a 1995 report to the NHC on
priorities for genetic services in New Zealand [39], and
highlighted the areas requiring further development to
meet the growing demand for genetic services and to
ensure the equitable, safe and appropriate provision of
medical genetics services to the New Zealand public. The
report noted the lack of a single agency taking an over-
arching view of genetic technologies and service delivery,
an absence that has implications for the effective regula-
tion of quality assurance in relation to genetic testing
[[38], p4].
Echoing some of the findings in the Sarfati report, the
NHC report highlighted the lack of a coordinated mecha-
nism for developing and evaluating new tests, the exclu-
sion of genetic tests from the Laboratory Services Schedule
and the absence of an organisation responsible for mak-
ing public funding decisions about these tests. It com-
mented on the risks raised by the increasing availability of
tests where utility and validity were uncertain or had been
inadequately assessed, and suggested these risks were
associated with the death of measures to ensure the qual-
ity of new tests
[[38], p13].
Problems with quality assurance mechanisms for labora-
tories were also identified. It found that laboratories car-
rying out low-volume tests might not be performing tests
often enough to maintain competency. Further, as
research laboratories need not be IANZ accredited, yet
sometimes perform clinical testing services, they may not
be subject to adequate quality assurance programmes. The
NHC considered that genetic testing particularly chal-
lenged the current system of quality assurance, due to its
rapid rate of development which demanded more fre-
quent reviews of laboratory competency than presently in
place [[38], p18].
Finally, the NHC Report noted that New Zealand needed
to consider the particular cultural concerns of the Maori
community in developing more effective quality assur-
ance measures. Genetic testing raises two potential con-
cerns for Maori. First, some Maori believe that genetic
technology may change the whakapapa, a spiritual value
that relates to Maori identity and which refers to geneal-
ogy, tribal histories and genetic inheritance. Second, that
for some Maori it may be culturally inappropriate to send
genetic samples outside New Zealand for testing [[38],
p23].
The report's major recommendations specifically relevant
to quality assurance and genetic testing were that:
￿ An assessment be made for the applicability of the
NHC's New Health Intervention Assessment (NHIA)
framework to the assessment of genetic technologies and
genetic tests;Australia and New Zealand Health Policy 2006, 3:13 http://www.anzhealthpolicy.com/content/3/1/13
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￿ Clinical validity and utility should direct the funding of
new genetic tests;
￿ The peer review process for genetic testing laboratory
accreditation be increased from four to two years to
accommodate rapid changes in technology;
￿ IANZ should accredit laboratories according to profes-
sional standards, such as those developed by the Human
Genetics Society of Australasia; and
￿ Protocols should be developed for each test approved
for use that cover, among other things, consent protocols,
when and how the test should be used and sensitivity to
cultural issues (particularly those of the Maori commu-
nity) [[38], p7].
Overview of Australian and New Zealand reviews
Not surprisingly, given the similarities in their regulatory
structures, the Australian and New Zealand reviews iden-
tified similar problems in many areas. Two major areas of
similarly were that some laboratories providing clinical
testing are not required to be accredited; and that there is
no effective system in place for ensuring compliance with
accreditation standards. A general theme in the reviews
was therefore the need to strengthen compliance mecha-
nisms. Finally, the lack of an oversight body for genetic
testing was identified as a problem in both New Zealand
and Australia. The ALRC recommended the establishment
of such a body, and its report provided a detailed account
of how this might be achieved and what functions the
proposed HGCA should have. New Zealand could draw
on this recommendation in establishing a similar body.
Alternatively there may be value in Australia and New
Zealand examining the option of developing a joint over-
sight body to advise on issues specific to genetic testing.
In other areas, the reviews differed in their focus. One
example is the ALRC Inquiry view that measures should
be put in place to address direct to the public test provi-
sion. This concern received relatively little attention in the
New Zealand reports, although it may well be a problem
in the New Zealand context as well.
Conclusion
Quality assurance is an important aspect of ensuring
patient safety and well-being in relation to genetic testing.
The reviews conducted of the Australian and New Zealand
schemes to promote quality assurance in genetic testing,
in general conclude that these schemes are working well.
Both countries have taken a proactive stance in recognis-
ing the need to continually monitor and evaluate their
regulatory frameworks and investigate measures to
improve them. Since these reviews have been conducted,
governments in both countries have taken steps to address
the problems identified. Given the rapid advances in the
field of genetic testing, we watch with interest as these
governments continue to develop their regulatory systems
governing quality assurance of genetic tests to ensure
patient safety and wellbeing.
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